Navigating Cancer Genetic Risk Factors and Common Questions about Breast Cancer With Kathy Pratt, BSN, RN, OCN®, CBCN®, ONN-CG

Kathy Pratt, BSN, RN, OCN®, CBCN®, ONN-CG

To celebrate Breast Cancer Awareness Month, Kathy Pratt, BSN, RN, OCN®, CBCN®, ONN-CG, a genetic patient navigator at UT Southwestern Simmons Comprehensive Cancer Center, discusses her role in reaching out to patients identified to have a greatly increased risk of developing cancer in their lifetimes. In this interview, she shares her advice in helping individuals prevent cancer, as well as her answers to her patients' common questions about breast cancer.

Virtual Tumor Board Improves Nurses’ Knowledge of Myelodysplastic Syndromes

An educational activity designed by i3 Health has demonstrated significant learning gains in the treatment and management of myelodysplastic syndromes (MDS) and has been presented at the 2021 Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit. A group of myeloid clonal hematopoietic disorders with a relatively heterogeneous spectrum of presentation, MDS, is associated with clinical problems resulting from cytopenias, which can evolve into acute myeloid leukemia. The incid...

Identifying Novel Therapies for Multiple Myeloma: Paul Richardson, MD

In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses some important factors in the development of drugs to target "the queen of immunological cancers," multiple myeloma, and why this disease is difficult to cure. Recently, he led the development and clinical trials of the novel targeted cytotoxic peptide-drug, melphalan flufenamide (Pepaxto®, Oncop...

Educational Needs in the Management of Relapsed/Refractory Follicular Lymphoma

Follicular lymphoma, an indolent, difficult-to-treat B-cell malignancy, is complicated by evolving disease subtypes. Patient outcomes can be hampered by the failure of the multidisciplinary team to establish consensus on the optimal timing, schedule, and length of follicular lymphoma treatment. In addition, the rapid pace of research makes it difficult to stay abreast of the latest and most clinically relevant therapies. This educational gap in the treatment and management of follicular lymphoma...

Melphalan Flufenamide for Multiple Myeloma: Paul Richardson, MD

Melphalan flufenamide, a newly approved peptide-drug conjugate for multiple myeloma, specifically targets chemotherapy to tumor cells like a warhead on a guided missile. In the following interview, Dr. Paul Richardson, the Clinical Program Leader and Director of Clinical Research of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute, discusses the use of melflufen (Pepaxto®, Oncopeptides AB) for multiple myeloma. Melflufen has its base in melphalan and the old technolo...

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.